Advanced Cancer Clinical Trials

A listing of 53 Advanced Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Advanced Cancer

1 - 12 of 53

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 53 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

NCT06540066

Recruiting

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended d... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California +11 locations

Conditions: Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor

Learn More ›

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575

Recruiting

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/20/2025

Locations: Providence Medical Foundation, Santa Rosa, California +97 locations

Providence Medical Foundation, Santa Rosa, California

Local Institution - 106, Chicago, Illinois

Local Institution - 103, Minneapolis, Minnesota

Local Institution - 105, Kansas City, Missouri

Veterans Affairs Medical Center (VAMC) - Durham, Durham, North Carolina

VA North Texas Healthcare System/Dallas VA Medical Center, Dallas, Texas

Local Institution - 179, Cachoeiro Do Itapemirim, Espírito Santo

Local Institution - 178, Belo Horizonte, Minas Gerais

Local Institution - 177, Porto Alegre, Rio Grande Do Sul

Local Institution - 182, Itajaí, Santa Catarina

Local Institution - 181, Salvador, Not set

Local Institution - 175, São Paulo, Not set

Local Institution - 527, Zagreb, Grad Zagreb

Local Institution - 525, Pula, Not set

Hopital Haut-Leveque - Maladies respiratoires, Pessac, Gironde

Local Institution - 553, Saint-Herblain Cedex, Loire-Atlantique

Centre Hospitalier Universitaire D' Angers Hôpital Larrey - PNEUMOLOGIE, Angers, Maine-et-Loire

Centre Hospitalier Universitaire de Poitiers, Poitiers, Poitou-Charentes

Local Institution - 559, Grenoble, Rhône-Alpes

Local Institution - 560, Villefranche Sur Saone, Rhône

Centre Hôspitalier de Bretagne Sud - Hôpital du Scorff, Lorient, Not set

APHM Hopital Nord, Marseille, Not set

CHU de Nantes - Hôpital Nord Laënnec (HGRL), Nantes cedex 1, Not set

Local Institution - 558, Quimper, Not set

Hôpital Bégin - Service d'Oncologie, Saint-Mandé, Not set

Local Institution - 577, Patras, Achaïa

Local Institution - 575, Athens, Attiki

Local Institution - 582, Athens, Attiki

Local Institution - 579, Haidari - Athens, Attiki

Local Institution - 576, Thessaloniki, Kentriki Makedonia

Local Institution - 580, Panorama, Not set

Local Institution - 581, Thessaloniki, Not set

Local Institution - 628, Tel Aviv-Yafo, Tel-Aviv

Local Institution - 625, Jerusalem, Yerushalayim

Local Institution - 629, Haifa, Not set

Local Institution - 627, Haifa, Not set

Local Institution - 626, Tel-Aviv, Not set

Local Institution - 778, Pesaro, Pesaro E Urbino

Local Institution - 780, Candiolo, Torino

Local Institution - 779, Milano, Not set

Local Institution - 777, Novara, Not set

Local Institution - 775, Perugia, Not set

Local Institution - 776, Roma, Not set

National Cancer Center, Gyeonggido [Kyonggi-do], Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Gangnam Severance Hospital, Yonsei University Health System, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Not set

Local Institution - 128, Tuxtla Gutiérrez, Chiapas

Local Institution - 129, Cdmx, Distrito Federal

Local Institution - 127, Col. Roma, Distrito Federal

Local Institution - 125, Toluca, Not set

Local Institution - 802, Breda, Noord-Brabant

Local Institution - 800, Amsterdam, Noord-Holland

Local Institution - 801, Nieuwegein, Utrecht

Local Institution - 650, Krakow, Malopolskie

Local Institution - 651, Gdynia, Pomorskie

Local Institution - 653, Lublin, Not set

Local Institution - 732, Cluj-Napoca, Cluj

Local Institution - 731, Ovidiu, Constanta

Local Institution - 729, Craiova, Dolj

Local Institution - 734, Craiova, Dolj

Local Institution - 730, Timisoara, Timis

Local Institution - 733, Iasi, Not set

Local Institution - 725, Sibiu, Not set

Local Institution - 728, Suceava, Not set

Local Institution - 753, Belgrade, Beograd

Local Institution - 754, Nis, Niaavski Okrug

Local Institution - 752, Kragujevac, Šumadijski Okrug

Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, A Coruña

Local Institution - 678, Malaga, Andalucía

Local Institution - 676, Oviedo, Asturias

Local Institution - 685, Palma de Mallorca, Baleares

Local Institution - 684, Valencia, Valenciana, Comunidad

Local Institution - 687, Barcelona, Not set

Local Institution - 681, Barcelona, Not set

Local Institution - 683, Barcelona, Not set

Local Institution - 675, Madrid, Not set

Local Institution - 679, Madrid, Not set

Hospital Universitario Virgen De La Macarena, Sevilla, Not set

Local Institution - 677, Valencia, Not set

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsuing City, Kaohsiung

China Medical University Hospital - Internal Medicine, Taichung City, Taichung Municipality

Chung Shan Medical University Hospital, Taichung City, Taichung

Local Institution - 355, Taichung City, Taichung

Local Institution - 377, Bangkok, Krung Thep Maha Nakhon [Bangkok]

Local Institution - 376, Chiang Mai, Not set

Local Institution - 375, Khon Kaen, Not set

Local Institution - 378, Songkhla, Not set

Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi, Ankara, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, Not set

Memorial Ankara Hastanesi Tibbi Onkoloji, Ankara, Not set

Ankara Liv Hospital Tibbi Onkoloji, Ankara, Not set

Ankara Bilkent Sehir Hastanesi Tibbi Onkoloji Klinigi, Ankara, Not set

Trakya Univ Hastanesi Ic Hastal, Edirne, Not set

Local Institution - 709, Istanbul, Not set

Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Not set

Istanbul Onkoloji Hastanesi Tibbi Onkoloji, Istanbul, Not set

Local Institution - 708, Izmir, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

Learn More ›

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06440005

Recruiting

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/13/2025

Locations: Sarah Cannon Research Center, Nashville, Tennessee +1 locations

Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor

Learn More ›

ALIGN for Older Adults with Cancer in SNFs

NCT06616298

Recruiting

The goal of this clinical trial is to learn if it is possible to deliver a palliative care intervention called ALIGN (Assessing and Listening to Individual Goals and Needs) to hospitalized older adults with advanced cancer who are discharged to a skilled nursing facility and their caregivers. The main questions it aims to answer are: * Can the investigator successfully deliver the ALIGN intervention in different skilled community nursing facilities? * Can the investigator successfully collect i... Read More

Gender:

ALL

Ages:

Between 18 years and 98 years

Trial Updated:

03/13/2025

Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado

Conditions: Advanced Cancer

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

NCT06707610

Recruiting

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

03/09/2025

Locations: D&H Cancer Research Center Llc, Margate, Florida +3 locations

Conditions: Advanced Cancer, Advanced Solid Tumor

Learn More ›

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

NCT06389097

Recruiting

The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be adm... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

03/06/2025

Locations: Johns Hopkins University, Baltimore, Maryland

Conditions: Prostate Cancer, Advanced Cancer

Learn More ›

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

NCT05204147

Recruiting

This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody, linked to a radioactive agent called actinium 225. M5A attaches to CEA positive cancer cells in a targeted way and delivers actinium 225 to kill them.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/06/2025

Locations: City of Hope Medical Center, Duarte, California

Conditions: Advanced Cancer, Metastatic Cancer

Learn More ›

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467

Recruiting

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/04/2025

Locations: California Cancer Associates for Research and Excellence, Encinitas, California +30 locations

California Cancer Associates for Research and Excellence, Encinitas, California

University of California San Diego UCSD, La Jolla, California

UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

Regents of the University of Colorado, Aurora, Colorado

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Insitute, Detroit, Michigan

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Stony Brook University, Stony Brook, New York

SCRI Oncology Partners - Nashville, Nashville, Tennessee

NEXT Oncology Virginia, Fairfax, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Institut Jules Bordet, Anderlecht, Not set

UZ Leuven - Campus Gasthuisberg, Leuven, Not set

GZA Hopsitals Campus Sint-Augustinus, Wilrijk, Not set

Centre de Lutte Contre le Cancer CLCC - Centre Georges Francois Leclerc (CGFL), Dijon, Not set

Centre Oscar Lambret, Lille, Not set

Centre Leon Berard, Lyon, Not set

Centre Antoine Lacassagne, Nice, Not set

Institut Gustave Roussy, Villejuif, Not set

Ospedale San Gerardo-ASST Monza, Monza, Not set

Istituto Clinico Humanitas, Rozzano, Not set

Gachon University Gil Medical Center, Incheon, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

NEXT Oncology Phase I Unit / IOB- Hospital Quironsalud Barcelona, Barcelona, Not set

Hospital Beata Maria Ana, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

START - Madrid, Madrid, Not set

Conditions: Advanced Cancer, Breast Cancer

Learn More ›

A Study of PHN-010 in Patients with Advanced Solid Tumors

NCT06457997

Recruiting

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2025

Locations: AdventHealth, Orlando, Florida +7 locations

Conditions: Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer

Learn More ›

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075

Recruiting

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: Sarah Cannon Research Institute, Denver, Colorado +9 locations

Conditions: Advanced Cancer

Learn More ›

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

Recruiting

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: The Angeles Clinic and Research Institute, Los Angeles, California +9 locations

Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer

Learn More ›

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171

Recruiting

The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/25/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +17 locations

Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)

Learn More ›

1 - 12 of 53